助手标题  
全文文献 工具书 数字 学术定义 翻译助手 学术趋势 更多
查询帮助
意见反馈
   浅表性膀胱癌 在 泌尿科学 分类中 的翻译结果: 查询用时:0.049秒
图标索引 在分类学科中查询
所有学科
泌尿科学
肿瘤学
心血管系统疾病
更多类别查询

图标索引 历史查询
 

浅表性膀胱癌     
相关语句
  superficial bladder cancer
    Mitomycin C in prophylaxis of recurrence of postoperative superficial bladder cancer
    丝裂霉素C膀胱内灌注预防浅表性膀胱癌术后复发
短句来源
    Bladder infusin of α interferon for the prevention of recurrence for superficial bladder cancer
    α-干扰素膀胱灌注预防浅表性膀胱癌术后复发的作用
短句来源
    Intravesical instillation of pirarubicin in the prophylaxis of local recurrence after resection of the superficial bladder cancer
    吡喃阿霉素膀胱内灌注预防浅表性膀胱癌术后复发
短句来源
    The clinical use of BCG-CWS and IL-2 for preventing recurrence of superficial bladder cancer
    BCG-CWS联合IL-2预防浅表性膀胱癌术后复发
短句来源
    Postoperative Prophylaxis of Recurrence for Superficial Bladder Cancer
    浅表性膀胱癌术后复发的预防
短句来源
更多       
  superficial bladder carcinoma
    47 postoperative patients with stages Ta to T1 primary superficial bladder carcinoma of grades 1or 2 were randomized into groups A: single 80 mg epirubicin;
    将 4 7例浅表性膀胱癌 (Ta~l,G1~ 2 )入选患者随机分为 3组 ,A组 ( 16例 )患者术后 6h内单次灌注表柔比星 80mg ; B组 ( 15例 )术后定期灌注表柔比星 4 0mg ,至术后 1年 ;
短句来源
    Methods A total of 36 patients with superficial bladder carcinoma (10 cases of T a and 26 of T 1;11 cases of G 1,20 of G 2 and 5 of G 3) underwent partial cystectomy.
    方法 浅表性膀胱癌 36例 ,Ta10例 ,T12 6例 ; G111例 ,G2 2 0例 ,G3 5例 ,均行膀胱部分切除。
短句来源
    Methods 49 cases of (stages Ta-1,grades1-2)superficial bladder carcinoma with average age of 60 were recruited. 34 Cases were received TURBT and 15 of which were given partial cystectomy.
    方法 浅表性膀胱癌(Ta -1,G1-2 ) 49例,平均年龄60岁,施行经尿道膀胱电切(TURBT) 3 4例,部分膀胱切除15例。
短句来源
    Methods187 patients with superficial bladder carcinoma after TUR-Bt operation were randomly divided into the group A (85 cases) and group B (102 cases). Patients of the group A were treated with instillation of Brucea Javanica oil emulsion;
    方法187例浅表性膀胱癌TUR-Bt术后患者随机分为A组(85例)和B组(102例),A组应用鸦胆子油乳膀胱灌注,B组灌注丝裂霉素预防肿瘤复发。
短句来源
    Early postoperative intravesical instillation of THP for the preventing recurrence of superficial bladder carcinoma
    浅表性膀胱癌术后早期膀胱内灌注吡柔比星预防复发疗效观察
短句来源
更多       
  superficial bladder tumor
    Clinical grade by UICC: superficial bladder tumor ( Tis ~ Tl) period 23 cases, invasive bladder tumor (12 ~T4) period 28 cases .
    临床分期按UICC标准:浅表性膀胱癌Tis~T1期23例,浸润性膀既癌h-T4期28例。
短句来源
    The Treatment of Superficial Bladder Tumor by Transurethral Resection
    经尿道电切术治疗浅表性膀胱癌
短句来源
    Methods: Partial cystectomy has been carried out for 13 cases of superficial bladder tumor and 5 cases of infiltrative cancer from April 1993 to December 1996.Before and in operation,intravesical instillation and submucosal local infiltrative injection with MTX have been used seperately.
    方法 :对 1 3例浅表性膀胱癌和 5例浸润性膀胱癌施以膀胱部分切除术 ,术前行 MTX膀胱灌注 ,术中和术后分别行 MTX膀胱粘膜下注射和直肠粘膜下注射 ,术后行小剂量 BCG膀胱灌注。
短句来源
    Methods We compared the effect of intravesical epirubicin or mitomycin C on tumor recurrence and disease free interval and their side effects after treatment of superficial bladder tumor.
    方法 了解表柔比星单次与多次灌注预防浅表性膀胱癌术后复发的长期疗效 ,并与丝裂霉素疗效比较。
短句来源
    The stromal expression of TIMP-2 would be an indicator of determining the recurrence of superficial bladder tumor.
    TIMP 2在间质中表达可作为判断浅表性膀胱癌复发的预后指标
短句来源
更多       
  primary superficial bladder carcinoma
    47 postoperative patients with stages Ta to T1 primary superficial bladder carcinoma of grades 1or 2 were randomized into groups A: single 80 mg epirubicin;
    将 4 7例浅表性膀胱癌 (Ta~l,G1~ 2 )入选患者随机分为 3组 ,A组 ( 16例 )患者术后 6h内单次灌注表柔比星 80mg ; B组 ( 15例 )术后定期灌注表柔比星 4 0mg ,至术后 1年 ;
短句来源
    Single instillation of epirubicin for the prophylaxis of recurrent primary superficial bladder carcinoma
    单次腔内灌注表柔比星预防浅表性膀胱癌术后复发
短句来源
    Single intravesical instillation of epirubicin for primary superficial bladder carcinoma:long-term results
    单次腔内灌注表阿霉素预防浅表性膀胱癌术后复发的长期随访研究
短句来源
    Submucosal injection plus single intravesical instillation of epirubicin for primary superficial bladder carcinoma recurrence
    表阿霉素黏膜下浸润注射加单次灌注预防浅表性膀胱癌术后复发的研究
短句来源
    Efficacy and safty of different dosages of intravesical epirubicin instillation for prevention of primary superficial bladder carcinoma from recurrence
    不同剂量表柔比星膀胱灌注预防浅表性膀胱癌复发的疗效与安全性
短句来源
更多       

 

查询“浅表性膀胱癌”译词为其他词的双语例句

 

查询“浅表性膀胱癌”译词为用户自定义的双语例句

    我想查看译文中含有:的双语例句
例句
为了更好的帮助您理解掌握查询词或其译词在地道英语中的实际用法,我们为您准备了出自英文原文的大量英语例句,供您参考。
  superficial bladder cancer
Presently, one of the most potent immunotherapies is the application of bacillus Calmette Guerin (BCG) to prevent recurrences of the superficial bladder cancer.
      
It could as possibly prove to be an effective intravesical treatment agent for superficial bladder cancer.
      
Substantial changes have been made in the therapeutic options for the management of superficial bladder cancer in the past 5 years.
      
Treatment goals for superficial bladder cancer are complete removal of the initial tumor, prevention of disease recurrence, and inhibition of progression to invasive disease.
      
This article reviews the pros and cons of a second staging TURBT and how it may impact the management of high-grade, low-stage superficial bladder cancer.
      
更多          
  superficial bladder carcinoma
(Bacillus Calmette Guérin) has proven to be effective in the prophylaxis of recurrence of superficial bladder carcinoma after transurethral resection and in the treatment of carcinoma in situ (C.I.S.) in man.
      
The main problems presented by superficial bladder carcinoma, its high recurrence rate and multifocal appearance, require treatment of the bladder as a whole.
      
Photodynamic therapy (PDT) is one such experimental treatment for superficial bladder carcinoma, involving the administration of a photosensitizer that accumulates in the tumor tissue, and subsequent irradiation of the tumor with light.
      
The results show that ALA-induced photosensitization has a high potential for photodynamic therapy (PDT) of superficial bladder carcinoma.
      
In intravesical therapy for superficial bladder carcinoma urothelial cells may, through the production of cytokines, contribute to the bacillus Calmette-Guérin (BCG)-induced local immunological reaction and associated antitumor efficacy.
      
更多          
  superficial bladder tumor
Large cooperative trials are more likely than series studied by small groups to bring about significant progress in the field of intravesical adjuvant chemotherapy of superficial bladder tumor
      
From October 1983 to September 1985, 84 patients with superficial bladder tumor (Ta, Tl, Tis) were treated with sequential instillation of mitomycin C (MMC) and adriamycin (ADM).
      
In superficial bladder tumor, abnormal expression of E-cadherin and a-catenin was demonstrated in 37 and 71% of the tumors, respectively.
      
Analysis of the expression of MAUB and MUC2 mucins in a human superficial bladder tumor specimen.
      
  其他


From January 1981 to December 1990 50 patients of superficial bladder cancer used Long-term intravesical instillation with mitomycin C in prophylaxis of recurrence after operation. The duration ranged from 16~94 (average 62) months. Complete response 60%, partial response 16%. No systemic effect on bone morrow suppression. Mitomycin C appeared to be a safe drug, but further studies are indicated when used as maintenance therapy.

对50例病人长期用丝裂霉素C膀胱内灌注预防浅表性膀胱癌术后复发,随访16~94个月,总有效率为76%。丝裂霉素C无骨髓抑制的全身副作用,持续应用证明安全有效。

23 cases of carcinoma of carcinoma of urinary bladder were treated postoperatively by intramuscular injection of IL-2 and intravesical irrigation of TTP from April 1989 to Oct 1992.Mean time of follow-up was 32 months.Only 2 cases had become recurrent(8.7%).Some complication of reversible leukopenia had happened.

对23例浅表性膀胱癌患者手术后联合应用IL-2肌注和TTP 灌注膀胱,预防膀胱癌术后复发。经随访平均32个月,复发2例,占8.7%。并发症仅少数病例有可复性的白细胞总数下降。

AbstractAlteration of p53 gene and the molecular biologi-cal difference between superficial and invasive bladdercancer were investigated by polymerase chain reaction-single strand conformation polymorphism analysis anddirect sequencing technique. p53 gene mutations wereexamined in exon region 5 to 8 in 21 bladder cancers.Only one of 14 superficial bladder cancers was found tohave p53 gene mutation. Four of 7 invasive bladdercancers with T_2,T_3and T_4were found to have p53 genemutation. p53 gene mutation was...

AbstractAlteration of p53 gene and the molecular biologi-cal difference between superficial and invasive bladdercancer were investigated by polymerase chain reaction-single strand conformation polymorphism analysis anddirect sequencing technique. p53 gene mutations wereexamined in exon region 5 to 8 in 21 bladder cancers.Only one of 14 superficial bladder cancers was found tohave p53 gene mutation. Four of 7 invasive bladdercancers with T_2,T_3and T_4were found to have p53 genemutation. p53 gene mutation was found none of the 4cancers with grade 1, only one of cancers with grade2, four of 12 cancers with grade 3. These results sug-gest that p53 gene play an important role in the devel-opment of human bladder cancer.

作者应用聚合酶链反应-单链构象多态性分析(PCR-SSCP)和直接测序等分子生物学技术,分析检测了21例膀胱移行上皮癌p53基因5~8外显子。结果,在14例浅表性膀胱癌中,发现1例(T_1期)p53基因突变;7例浸润性膀胱癌中,4例发现p53基因突变,其中T_2期1例,T_3期2例,T_4期1例。4例G_1级膀胱癌无一例检出p53突变,5例G_2级膀胱癌1例检出p53突变,12例G_3级肿瘤4例发现p53基因突变。结果表明:p53基因突变在膀胱癌的发生发展中起着重要作用。

 
<< 更多相关文摘    
图标索引 相关查询

 


 
CNKI小工具
在英文学术搜索中查有关浅表性膀胱癌的内容
在知识搜索中查有关浅表性膀胱癌的内容
在数字搜索中查有关浅表性膀胱癌的内容
在概念知识元中查有关浅表性膀胱癌的内容
在学术趋势中查有关浅表性膀胱癌的内容
 
 

CNKI主页设CNKI翻译助手为主页 | 收藏CNKI翻译助手 | 广告服务 | 英文学术搜索
版权图标  2008 CNKI-中国知网
京ICP证040431号 互联网出版许可证 新出网证(京)字008号
北京市公安局海淀分局 备案号:110 1081725
版权图标 2008中国知网(cnki) 中国学术期刊(光盘版)电子杂志社